Senaparib is under clinical development by IMPACT Therapeutics and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to GlobalData, Phase II drugs for Metastatic Castration-Resistant Prostate Cancer (mCRPC) have a 34% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Senaparib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Senaparib is under development for the treatment of solid tumours including small cell lung cancer, metastatic castration-resistant prostate cancer (mCRPC), ovarian cancer, fallopian tube cancer, epithelial ovarian cancer, peritoneal cancer, lung cancer and breast cancer. The drug candidate targets PARP (Poly(ADP-ribose) polymerase). The drug candidate was also under development for melanoma, prostate cancer and liver cancer. It is administered through oral route.
IMPACT Therapeutics overview
IMPACT Therapeutics (IMPACT) is a developer of therapeutics to treat cancer and other life-threatening diseases. The company provides products such as microtubule inhibitors, PARP-1 inhibitors, and Hedgehog pathway inhibitors for oncology. Its PARP-1 inhibitor is an oral bioavailability; and IMP04297 is an efficacious in several animal cancer models. The company also develops IMP3138, a small molecular microtubule inhibitor clinical candidate with advantages in vitro and in vivo over paclitaxel. It also operates oncology drug discovery and several anticancer drug development projects. IMPACT is headquartered in Nanjing, China.
For a complete picture of Senaparib’s drug-specific PTSR and LoA scores, buy the report here.